Advances in acute ischemic stroke therapy
Y Xiong, AK Wakhloo, M Fisher - Circulation research, 2022 - Am Heart Assoc
The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …
Tenecteplase thrombolysis for acute ischemic stroke
Tenecteplase is a fibrinolytic drug with higher fibrin specificity and longer half-life than the
standard stroke thrombolytic, alteplase, permitting the convenience of single bolus …
standard stroke thrombolytic, alteplase, permitting the convenience of single bolus …
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open …
Summary Background Mobile stroke units (MSUs) equipped with a CT scanner reduce time
to thrombolytic treatment and improve patient outcomes. We tested the hypothesis that …
to thrombolytic treatment and improve patient outcomes. We tested the hypothesis that …
Artificial intelligence for decision support in acute stroke—current roles and potential
The identification and treatment of patients with stroke is becoming increasingly complex as
more treatment options become available and new relationships between disease features …
more treatment options become available and new relationships between disease features …
Ischemic core thresholds change with time to reperfusion: a case control study
Introduction We aimed to identify whether acute ischemic stroke patients with known
complete reperfusion after thrombectomy had the same baseline computed tomography …
complete reperfusion after thrombectomy had the same baseline computed tomography …
Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study
Background and hypothesis Intravenous thrombolysis with alteplase remains standard care
prior to thrombectomy for eligible patients within 4.5 h of ischemic stroke onset. However …
prior to thrombectomy for eligible patients within 4.5 h of ischemic stroke onset. However …
Tenecteplase or alteplase: what is the thrombolytic agent of the future?
A Mahmood, KW Muir - Current Treatment Options in Neurology, 2022 - Springer
Purpose of review Alteplase has been the thrombolytic of choice for acute ischaemic stroke
for more than two decades. A thrombolytic which is easier to administer and with improved …
for more than two decades. A thrombolytic which is easier to administer and with improved …
Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials
H Liang, X Wang, X Quan, S Chen, B Qin… - Frontiers in …, 2023 - frontiersin.org
Background The optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS)
has yet to be established. Therefore, we included the latest randomized controlled trials …
has yet to be established. Therefore, we included the latest randomized controlled trials …
Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials
SB Coutts, E Berge, BCV Campbell… - … Journal of Stroke, 2018 - journals.sagepub.com
Alteplase has been the mainstay of thrombolytic treatment since the National Institutes of
Neurological Disorders and Stroke trial was published in 1995. Over recent years, several …
Neurological Disorders and Stroke trial was published in 1995. Over recent years, several …
Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window
Objective To assess the utility of IV thrombolysis (IVT) treatment in patients with acute
ischemic stroke (AIS) with unclear symptom onset time or outside the 4.5-hour time window …
ischemic stroke (AIS) with unclear symptom onset time or outside the 4.5-hour time window …